Navigation Links
Nuvo announces second quarter 2008 financial results
Date:7/31/2008

reased 79% to $4.3 million compared with $2.4 million for the six-months ended June 30, 2007. The increase is primarily due to significantly higher sales of Pennsaid to our Greek distributor which launched Pennsaid in the first half of 2007 and higher sales to our Canadian distributor.

As a result of the increased sales volumes, gross margin on product sales improved significantly to $0.8 million and $1.7 million for the three and six-months ended June 30, 2008 compared to $0.1 million in both the three and six-month periods ended June 30, 2007.

Total operating expenses, excluding foreign currency gains and losses, for three and six-months ended June 30, 2008 were $3.9 million and $7.6 million, an increase from $3.6 million and $7.3 million for three and six-months ended June 30, 2007. The increase in the three and six-month periods is due to higher spending on research and development activities. This highlights the impact of the Company's efforts during the third and fourth quarters of 2007 to focus its resources on research activities rather than administrative costs. For the six-month period, research and development expenditures represented 56% of operating expenses (before currency gains and losses) versus 47% in the comparative six-month period of 2007.

Research and development expenses were $2.1 million and $4.2 million for the three and six-months ended June 30, 2008 an increase of 24% and 22% compared with $1.7 million and $3.5 million for the three and six-months ended June 30, 2007. The majority of spending for the current three and six-month periods is related to the on-going studies to address the conditions raised by the FDA in the Pennsaid Approvable Letter. During the first two quarters, the Company made excellent progress towards the completion of several of the Short and Long Term Studies required for the Complete Response.

SG&A expenses decreased to $1.2 million and $2.3 million for the three and six-months ended June
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
2. Cardiva Medical Announces Presentation at BMO Capital Markets 2008 Focus on Healthcare Conference
3. Lyriana Announces Antidepressants Now Linked to Declining Libido in Women
4. Hologic Announces Third Quarter Fiscal 2008 Operating Results
5. VendorClear™ Announces Limited Release of New Products for Healthcare Facilities and Vendor Representatives
6. The Quantum Group Announces 2nd Statewide Contract
7. STERIS Corporation Announces Fiscal 2009 First Quarter Results
8. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
9. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
10. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
11. Align Technology Announces Second Quarter Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... New York (PRWEB) August 28, 2014 An ... back and neck issues, Cloud 9 Spine offers their resources ... spine problems can quickly become a brick wall of discouragement ... for a professional opinion, Cloud 9 Spine offers ... proprietary technology merged with human interaction that sets Cloud 9 ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is proud to ... Tiaras, to benefit the Immune Deficiency Foundation (IDF) Walk ... in Foley Square, New York. IDF is the ... (PI) are a group of more than 200 rare, ... immune system is missing or functions improperly. In ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/27/2014)... Asheville, NC (PRWEB) August 28, 2014 ... for companies to acquire as part of a ... business. Aeroflow is positioned for taking ownership of ... foundation to increase economies of scale. , Last ... an agreement with Hometown Respiratory to increase service ...
(Date:8/27/2014)... Spine Guide has built a reputation for itself ... health. Now, the e-health site will offer new surgical ... pain symptoms. Spine Guide specializes in three types of ... surgery. , Some of the most common back pain ... radiating down the leg, inability to stand up straight, ...
Breaking Medicine News(10 mins):Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Spine Guide Offering New Overview of Surgical Options For Back Pain 2
... Switzerland and Brussels, Belgium, 9 April 2008: The European ... European CanCer Organisation have united forces to host a ... best and most updated scientific data for everyone working ... providing all cancer patients with equal access to high-quality ...
... 2008 Ever wonder if,your doctor personally follows the ... to the recent "Life ... supplemented" Healthcare,Professionals (HCP) Impact ... behaviors, with three of the top shared healthy behaviors,being: ... regularly (73,percent) and taking vitamins and other supplements (72 ...
... Research, Programs for #1 Cause of,Fatal and Nonfatal Injuries ... A broad-based,coalition of nonprofit organizations dedicated to improving the ... of S. 845, the Safety,of Seniors (SOS) Act, clearing ... point: each year, one in three older Americans (65 ...
... counterintuitive to exercise when suffering with joint pain, but ... most people suffering from arthritis. A recent study ... regular exercise, specifically the Arthritis Foundation Exercise Program, is ... pain. This is good news for the aging ...
... April 8, 2008 The Procter &,Gamble Company (NYSE: ... in the quarterly dividend from thirty-five cents ($0.35) to forty,cents ... Series A and Series,B ESOP Convertible Class A Preferred Stock ... shareholders of record at the close of business on,April 18, ...
... Chinese studies show cancer treatment extended survival time in ... combination of the active ingredients in reishi mushrooms and ... survival time of mice with sarcomas, two Chinese studies ... fat, muscle, blood vessels, or other connective or supportive ...
Cached Medicine News:Health News:European Society for Medical Oncology and European CanCer Organization join forces 2Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 2Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 3Health News:Elder Falls Bill Passes Congress, Heads to President 2Health News:Elder Falls Bill Passes Congress, Heads to President 3Health News:Physical activity is natural pain reliever for arthritis 2Health News:Green Tea, Mushroom Extract Combo Slows Sarcomas 2
(Date:8/27/2014)... 2014 Kewaunee Scientific Corporation (Nasdaq: ... its quarterly cash dividend by 9% to twelve cents ... beginning with the dividend payable on September 22, 2014 ... on September 8, 2014. About Kewaunee ... Scientific Corporation is a recognized global leader in the ...
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014 /PRNewswire/ ... Co., Ltd, ("Menovo") today announced they had entered into ... primarily targeting the United States ... Menovo will jointly develop products for Amerigen to commercialize ... will be responsible for manufacturing API and finished product ...
(Date:8/27/2014)... 27, 2014 Ambit Biosciences (Nasdaq: AMBI ), ... targeting unmet needs in oncology, autoimmune and inflammatory disease, today ... Conference to be held at The New York Palace Hotel ... 3-4, 2014. Alan Fuhrman , Ambit,s CFO, ... drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
The High Pure Viral RNA Kit is intended for general laboratory use and is designed to purify viral RNA from serum or plasma. Viral RNA is used for RT-PCR analysis directly after elution in nuclease-f...
... This revolutionary product will provide you ... type of electroretinogram, visual evoked potential, ... ganzfeld will allow you to perform ... on-off, double flash, photopic negative response, ...
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe...
... is designed for high throughput microplate processing. ... S60 Stacker that handles up to 60 ... base model is equipped with a dual ... units may be interfaced to increase flexibility ...
Medicine Products: